Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: Updated efficacy and safety results of the phase 3 CANDOR study Meeting Abstract
| Authors: | Dimopoulos, M. A.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D. S.; Weisel, K.; Gavriatopoulou, M.; Oriol, A.; Rabin, N. K.; Nooka, A.; Qi, M.; Ding, B. F.; Zahlten-Kumeli, A.; Usmani, S. Z. |
| Abstract Title: | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: Updated efficacy and safety results of the phase 3 CANDOR study |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547202236 |
| DOI: | 10.1182/blood-2020-137602 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 26 -- Source: Wos |
